Summary & Overview
HCPCS C9257: Injection, bevacizumab 0.25 mg
HCPCS Level II code C9257 denotes the injection of bevacizumab in a 0.25 mg unit. Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody used across oncology and certain ophthalmologic applications; a code for a small drug quantity like C9257 enables itemized billing for incremental dosing and supports facility and professional payment workflows. Nationally, accurate coding for biologic injections affects drug cost reporting, prior authorization processes, and patient cost-sharing calculations.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical use and administration setting, typical billing considerations tied to a unit-based HCPCS drug code, and what to expect in payer coverage patterns. The publication outlines benchmark elements such as common payer approaches to unit pricing, coding validation checkpoints, and links between dose-based codes and prior authorization requirements. It also summarizes relevant policy drivers that influence nationwide utilization and reimbursement of injectable biologics.
This summary serves clinicians, billing managers, and policy analysts seeking a concise reference to the code's clinical meaning, typical site of service, and the payer landscape nationally. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9257 represents injection of bevacizumab, 0.25 mg. This billing code corresponds to a parenteral therapeutic administration of the monoclonal antibody bevacizumab at the specified small dose increment.
Service Type: Injection, therapeutic (parenteral)
Typical Site of Service: Outpatient clinic or physician office (ambulatory infusion/administration setting)
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with neovascular (wet) age-related macular degeneration presents to an ophthalmology clinic for intravitreal therapy. The retina specialist reviews recent optical coherence tomography and visual acuity, documents active subretinal fluid consistent with disease activity, and orders intravitreal bevacizumab. The medication is prepared as a sterile aliquot at 0.25 mg per dose for ocular administration. The patient is positioned in a minor procedure room or ambulatory surgical center; the eye is prepped with topical anesthetic and antiseptic, a lid speculum is inserted, and a measured intravitreal injection of bevacizumab is administered under aseptic technique. Post-injection care includes intraocular pressure check, instruction on signs of endophthalmitis, and a follow-up visit in 4–6 weeks for reassessment and potential repeat injection. Billing uses HCPCS Level II code C9257 to report bevacizumab by amount (injection, bevacizumab, 0.25 mg) in the outpatient or ambulatory setting; documentation must support dose, lot number, route (intravitreal), laterality, and clinical indication for medical necessity determination.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of the prepared bevacizumab vial is discarded prior to administration and the payer requires reporting of waste. |